Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed"

被引:59
作者
Bjerre, LM
LeLorier, J
机构
[1] CHU Montreal, Ctr Rech, Pharmacoepidemiol & Pharmacoecon Res Unit, Montreal, PQ H2W 1T8, Canada
[2] McGill Univ, Fac Med, Dept Epidemiol & Biostat, Montreal, PQ H3A 1A2, Canada
关键词
D O I
10.1136/bmj.320.7233.503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Results of epidemiological studies need to be expressed in understandable terms if they are to be of practical use to clinicians and policy makers Case-control studies are often used to stud) adverse effects of treatment; odds ratios from these are used to express the magnitude of adverse effects, but ar-e not intuitively understandable estimates of risk A more understandable and informative means of expressing the risk of adverse events in case-control studies is "the number of patients needed to be treated for one additional patient to be harmed" This is calculated from the odds ratio and the unexposed event rate-that is, the rate of occurrence of the adverse event of interest in people not exposed to the treatment.
引用
收藏
页码:503 / 506
页数:4
相关论文
共 11 条
  • [1] Appetite-suppressant drugs and the risk of primary pulmonary hypertension
    Abenhaim, L
    Moride, Y
    Brenot, F
    Rich, S
    Benichou, J
    Kurz, X
    Higenbottam, T
    Oakley, C
    Wouters, E
    Aubier, M
    Simonneau, G
    Begaud, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) : 609 - 616
  • [2] Confidence intervals for the number needed to treat
    Altman, DG
    [J]. BRITISH MEDICAL JOURNAL, 1998, 317 (7168) : 1309 - 1312
  • [3] [Anonymous], 1997, CAN MED ASSOC J, DOI DOI 10.1136/BMJ.313.7069.1410
  • [4] THE ASSOCIATION OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS WITH UPPER GASTROINTESTINAL-TRACT BLEEDING
    CARSON, JL
    STROM, BL
    SOPER, KA
    WEST, SL
    MORSE, ML
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (01) : 85 - 88
  • [5] FARLEY TMM, 1995, LANCET, V346, P1582
  • [6] RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS
    JICK, H
    JICK, SS
    GUREWICH, V
    MYERS, MW
    VASILAKIS, C
    [J]. LANCET, 1995, 346 (8990): : 1589 - 1593
  • [7] AN ASSESSMENT OF CLINICALLY USEFUL MEASURES OF THE CONSEQUENCES OF TREATMENT
    LAUPACIS, A
    SACKETT, DL
    ROBERTS, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (26) : 1728 - 1733
  • [8] RISK OF UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION ASSOCIATED WITH INDIVIDUAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    RODRIGUEZ, LAG
    JICK, H
    [J]. LANCET, 1994, 343 (8900) : 769 - 772
  • [9] Sackett D L., 1996, Evid Based Med, V1, P164, DOI [DOI 10.1136/EBM.1996.1.164, 10.1136/ebm.1996.1, DOI 10.1136/EBM.1996.1]
  • [10] Sackett DL., 1991, CLIN EPIDEMIOLOGY BA